BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 24844147)

  • 1. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.
    Subramaniam SR; Vergnes L; Franich NR; Reue K; Chesselet MF
    Neurobiol Dis; 2014 Oct; 70():204-13. PubMed ID: 25016198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism.
    Agrawal S; Dixit A; Singh A; Tripathi P; Singh D; Patel DK; Singh MP
    Mol Neurobiol; 2015 Dec; 52(3):1619-1628. PubMed ID: 25370934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Bian M; Liu J; Hong X; Yu M; Huang Y; Sheng Z; Fei J; Huang F
    PLoS One; 2012; 7(6):e39953. PubMed ID: 22792139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
    Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys.
    Chen M; Wang T; Yue F; Li X; Wang P; Li Y; Chan P; Yu S
    Neuroscience; 2015 Feb; 286():383-92. PubMed ID: 25498223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
    Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
    Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
    Park JS; Choe K; Lee HJ; Park TJ; Kim MO
    J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.
    Hebron ML; Lonskaya I; Moussa CE
    Hum Mol Genet; 2013 Aug; 22(16):3315-28. PubMed ID: 23666528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.
    Huang HJ; Wang YT; Lin HC; Lee YH; Lin AM
    Mol Neurobiol; 2018 Jan; 55(1):138-144. PubMed ID: 28822080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.